Gossamer Bio(GOSS) ZACKS·2025-03-13 22:10Company Performance - Gossamer Bio reported a quarterly loss of 0.17, and an improvement from a loss of 9.38 million for the quarter ended December 2024, exceeding the Zacks Consensus Estimate by 19.63%, compared to zero revenues a year ago [2] - Gossamer Bio has surpassed consensus EPS estimates two times over the last four quarters [2] Stock Performance - Gossamer Bio shares have increased by approximately 48.1% since the beginning of the year, contrasting with a decline of 4.8% in the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is -5 million in revenues, and for the current fiscal year, it is -23.66 million in revenues [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which Gossamer Bio belongs, is currently ranked in the top 26% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Gossamer Bio's stock performance [5]